A review on: Ritlecitinib
Abstract & Details
Research Area
Pharmaceutical Science
Keywords
Alopecia aerta
ritlecitinib.
Abstract
Alopecia areata (AA) is an autoimmune condition that causes patchy hair loss, affecting up to 147 million people globally. Currently, there are no treatments approved by US Food and Drug Administration (FDA) specific for AA, and there are few effective therapeutic options for widespread and persistent illness. There is an ongoing need for a treatment that demonstrates a good clinical response with a benefit-risk ratio that is suitable for long-term use, especially for patients with chronic, extensive disease. Several clinical trials and case studies that have assessed Janus kinase inhibitors have had encouraging results. Ritlecitinib, a selective JAK3/TEC kinase inhibitor has been demonstrated to inhibit the action of signaling molecules and immune cells that are responsible for hair loss in people with alopecia areata. Furthermore, several clinical trials are investigating the utility of ritlecitinib in patients with vitiligo, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Advantages of using ritlecitinib when compared with other non-selective JAK inhibitors include avoiding JAK1/JAK2 inhibition’s clinical repercussions, which include pharmacodynamic effects such as increased cholesterol and liver enzymes, and those related to JAK2 inhibition (thrombocytopenia, anemia). Treatment with Ritlecitinib 50 mg and 30 mg daily for 24 weeks has been shown to induce hair regrowth with a significant proportion of patients reaching SALT 20 (≤20% scalp hair loss) after six months of therapy compared to placebo. Additional research is needed for long-term effects.
License
This work is licensed under a Creative
Commons
Attribution-ShareAlike 4.0 International License.
Author Information
| # | Name | Institute / Affiliation |
|---|---|---|
| 1 | Rutuja shivaji Karad | Matoshri college of pharmacy eklahare Nashik |
| 2 | Shraddha Bhavsar | Matoshri college of pharmacy eklahare Nashik |
How to Cite
Use the following formats to cite this article in your research.
APA Style
Karad, Rutuja shivaji & Bhavsar, Shraddha (2026). A review on: Ritlecitinib. International Journal of Advance Research and Innovative Ideas In Education, 12(1), 1170-1176.
MLA Style
Karad, Rutuja shivaji, and Shraddha Bhavsar. "A review on: Ritlecitinib." International Journal of Advance Research and Innovative Ideas In Education, vol. 12, no. 1, 2026, pp. 1170-1176.
IEEE Style
Rutuja shivaji Karad and Shraddha Bhavsar, "A review on: Ritlecitinib," International Journal of Advance Research and Innovative Ideas In Education, vol. 12, no. 1, pp. 1170-1176, 2026.
Vancouver Style
Karad Rutuja shivaji, Bhavsar Shraddha. A review on: Ritlecitinib. International Journal of Advance Research and Innovative Ideas In Education. 2026;12(1):1170-1176.
Harvard Style
Karad, Rutuja shivaji & Bhavsar, Shraddha (2026) 'A review on: Ritlecitinib', International Journal of Advance Research and Innovative Ideas In Education, 12(1), pp. 1170-1176.
Chicago Style
Karad, Rutuja shivaji and Shraddha Bhavsar. "A review on: Ritlecitinib." International Journal of Advance Research and Innovative Ideas In Education 12, no. 1 (2026): 1170-1176.
Turabian Style
Karad, Rutuja shivaji and Shraddha Bhavsar. "A review on: Ritlecitinib." International Journal of Advance Research and Innovative Ideas In Education 12, no. 1 (2026): 1170-1176.
Related Research
FORMULATION AND EVALUATION OF MUCOADHESIVE MICROSPHERE DRUG DELIVERY SYSTEM OF LOSARTAN
Download PDF
Formulation and Characterization of Nanoparticle Based Systems for Enhanced Oral Delivery of Acalabrutinib
Download PDF
Formulation and Evaluation of Solid-Self Nano Emulysifying Drug Delivery System of poorly soluble drug Rosuvastatin for increased its bioavailability
Download PDF
Formulation, Characterization & Evaluation of Polymeric Amorphous Films of Itraconazole by Using Cellulosic Polymers
Download PDF